Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms.

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Opinion on Emerging Drugs Pub Date : 2025-06-01 DOI:10.1080/14728214.2025.2508994

Nicola Fazio, Anna La Salvia

{"title":"Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms.","authors":"Nicola Fazio, Anna La Salvia","doi":"10.1080/14728214.2025.2508994","DOIUrl":null,"url":null,"abstract":"Introduction: In the era of precision medicine, a molecularly targeted therapeutical approach is still missing in the field of neuroendocrine neoplasms (NENs) other than for radioligand therapy (RLT). So far sunitinib is the only tyrosine kinase inhibitor (TKI) available in clinical practice for NENs in Western countries, limited to advanced, progressing pancreatic neuroendocrine tumors (NETs). A few TKIs worldwide reached an advanced stage of clinical investigation with promising results.Areas covered: This narrative review is an updated analysis about the status of TKIs in the most advanced stage of clinical investigation in NENs. Our work is focused specifically on a critical analysis of TKIs investigated in phase III clinical trials, such as Axitinib, Surufatinib, and Cabozantinib.Expert opinion: The Expert Opinion section of our manuscript is a critical overview of the results coming from phase II and III clinical trials with Axitinib, Surufatinib, and Cabozantinib, and, it is mainly centered on strategies of investigation of these TKIs, including geographical areas and indirect comparison about study design.","PeriodicalId":12292,"journal":{"name":"Expert Opinion on Emerging Drugs","volume":" ","pages":"149-157"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Emerging Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14728214.2025.2508994","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In the era of precision medicine, a molecularly targeted therapeutical approach is still missing in the field of neuroendocrine neoplasms (NENs) other than for radioligand therapy (RLT). So far sunitinib is the only tyrosine kinase inhibitor (TKI) available in clinical practice for NENs in Western countries, limited to advanced, progressing pancreatic neuroendocrine tumors (NETs). A few TKIs worldwide reached an advanced stage of clinical investigation with promising results.

Areas covered: This narrative review is an updated analysis about the status of TKIs in the most advanced stage of clinical investigation in NENs. Our work is focused specifically on a critical analysis of TKIs investigated in phase III clinical trials, such as Axitinib, Surufatinib, and Cabozantinib.

Expert opinion: The Expert Opinion section of our manuscript is a critical overview of the results coming from phase II and III clinical trials with Axitinib, Surufatinib, and Cabozantinib, and, it is mainly centered on strategies of investigation of these TKIs, including geographical areas and indirect comparison about study design.

查看原文本刊更多论文

新出现的酪氨酸激酶抑制剂用于治疗神经内分泌肿瘤。

导论：在精准医学时代，除了放射配体治疗（RLT）外，神经内分泌肿瘤（NENs）领域还缺乏一种分子靶向治疗方法。到目前为止，舒尼替尼是西方国家临床实践中唯一可用于NENs的酪氨酸激酶抑制剂（TKI），仅限于晚期进展性胰腺神经内分泌肿瘤（NETs）。世界范围内的一些tki已进入临床研究的后期阶段，并取得了令人鼓舞的结果。涵盖领域：这篇叙述性综述是对NENs临床研究最晚期tki状态的最新分析。我们的工作重点是在III期临床试验中对TKIs进行批判性分析，如阿西替尼、舒法替尼和卡博赞替尼。专家意见：我们手稿中的专家意见部分是对阿西替尼、舒法替尼和卡博赞替尼的II期和III期临床试验结果的重要概述，主要集中在这些tki的调查策略上，包括地理区域和研究设计的间接比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.